Germany Peripheral Neuropathy Market

ID: MRFR/HC/49645-HCR
200 Pages
Nidhi Mandole
Last Updated: February 06, 2026
Germany Peripheral Neuropathy Market Research Report: Size, Share, Trend Analysis By Types (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, HIV/AIDS Associated Peripheral Neuropathy), By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies, Others), and By End-user (Hospitals and Clinics, Ambulatory Centers, Others) - Growth Outlook & Industry Forecast 2025 To 2035
Germany Peripheral Neuropathy Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.62%
2024 Market Size$ 176.4 Million
2025 Market Size$ 189.84 Million
2035 Market Size$ 395.5 Million
Key Players
Pfizer Inc
Johnson & Johnson
Boehringer Ingelheim
AstraZeneca
Novartis AG
Eli Lilly and Company
Trends
  • Rising Incidence of Diabetes
  • Technological Advancements in Treatment
  • Focus on Personalized Medicine
Opportunities
  • Rising Healthcare Expenditure
  • Emergence of Novel Therapeutics
  • Increased Awareness and Diagnosis
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
      1. 4.1.1 Diabetic Peripheral Neuropathy
      2. 4.1.2 Chemotherapy-induced Peripheral Neuropathy
      3. 4.1.3 Idiopathic Peripheral Neuropathy
      4. 4.1.4 HIV/AIDS Associated Peripheral Neuropathy
    2. 4.2 Food, Beverages & Nutrition, BY Treatment (USD Million)
      1. 4.2.1 Pharmacological Therapies
      2. 4.2.2 Non-Pharmacological Therapies
      3. 4.2.3 Others
    3. 4.3 Food, Beverages & Nutrition, BY End User (USD Million)
      1. 4.3.1 Hospitals and Clinics
      2. 4.3.2 Ambulatory Centers
      3. 4.3.3 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Pfizer Inc (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Johnson & Johnson (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Boehringer Ingelheim (DE)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 AstraZeneca (GB)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Novartis AG (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Eli Lilly and Company (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Teva Pharmaceutical Industries Ltd (IL)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Sanofi (FR)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Mylan N.V. (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 GERMANY MARKET ANALYSIS BY TYPE
    3. 6.3 GERMANY MARKET ANALYSIS BY TREATMENT
    4. 6.4 GERMANY MARKET ANALYSIS BY END USER
    5. 6.5 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
    8. 6.8 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    10. 6.10 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
    11. 6.11 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
    12. 6.12 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
    13. 6.13 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 (% SHARE)
    14. 6.14 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 TO 2035 (USD Million)
    15. 6.15 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 (% SHARE)
    16. 6.16 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
      3. 7.2.3 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Germany Peripheral Neuropathy Market Segmentation

Germany Peripheral Neuropathy Market By Type (USD Million, 2025-2035)

  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • HIV/AIDS Associated Peripheral Neuropathy

Germany Peripheral Neuropathy Market By Treatment (USD Million, 2025-2035)

  • Pharmacological Therapies
  • Non-Pharmacological Therapies
  • Others

Germany Peripheral Neuropathy Market By End User (USD Million, 2025-2035)

  • Hospitals and Clinics
  • Ambulatory Centers
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.